Dx&Vx (DXVX) Partners with Over 40 Global Companies at BIO USA, "Focused Discussions on Overseas Out-Licensing Deals"
Oral obesity drug with world-first mechanism of action unveiled, drawing strong on-site interest Following successful Phase 1 clinical results, global discussions on OVM-200 expand Meetings with over 40 companies, including major pharmaceutical...